Emergent BioSolutions Initiates Phase 1 Clinical Study of Zika Virus Immune Globulin Therapeutic
ZIKV-IG granted Fast Track designation by the U.S. Food and Drug Administration GAITHERSBURG, Md. , July 31, 2018 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced the...
Emergent BioSolutions to Release Second Quarter 2018 Financial Results and Conduct a Conference Call on August 2, 2018
GAITHERSBURG, Md. , July 18, 2018 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, August 2, 2018 at 5:00 pm (Eastern Time) to discuss the...
Emergent BioSolutions to Participate in the Goldman Sachs 39th Annual Global Healthcare Conference
GAITHERSBURG, Md. , June 08, 2018 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) announced today that a member of the company’s senior management team will present a corporate...
Emergent BioSolutions Announces $50 Million Expansion of Baltimore Fill/Finish Facility
Multi-year investment will support growth of contract development and manufacturing capabilities GAITHERSBURG, Md. , June 07, 2018 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today...
CEPI Awards $25 Million Contract to Profectus BioSciences and Emergent BioSolutions to Develop Nipah Virus Vaccine
OSLO, Norway and BALTIMORE and GAITHERSBURG, Md., May 24, 2018 (GLOBE NEWSWIRE) — CEPI—the Coalition for Epidemic Preparedness Innovations—today announced a collaboration with Profectus...
Emergent BioSolutions to Hold Annual Meeting of Stockholders on Thursday, May 24, 2018 at 9:00 AM EDT; Webcast Will Be Available
GAITHERSBURG, Md. , May 10, 2018 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) has announced that it will hold its Annual Meeting of Stockholders on Thursday, May 24, 2018 beginning...
Emergent BioSolutions Reports First Quarter 2018 Financial Results
Reaffirms full year 2018 financial forecast and operational goals Provides Q2 2018 revenue forecast of $205M-$230M GAITHERSBURG, Md. , May 03, 2018 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc....
Emergent BioSolutions to Release First Quarter 2018 Financial Results and Conduct a Conference Call on May 3, 2018
GAITHERSBURG, Md. , April 19, 2018 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, May 3, 2018 at 5:00 pm (Eastern Time) to discuss the...
Emergent BioSolutions Announces Successful Completion of Mutual Recognition Procedure for Market Authorisation of BioThrax in European Countries
GAITHERSBURG, Md , USA–(BUSINESS WIRE)–Apr. 12, 2018– Emergent BioSolutions Inc. (NYSE:EBS) today announced the successful completion of the Mutual Recognition Procedure (MRP) for...
Emergent BioSolutions Announces Executive Management Changes That Enhance Execution of Company’s Growth Strategy
GAITHERSBURG, Md. , March 26, 2018 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced executive management changes that continue to align its organizational structure to...
Emergent BioSolutions Awarded One-Year CDC Contract Valued at $26 Million for Vaccinia Immune Globulin Program
GAITHERSBURG, Md. , Feb. 28, 2018 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced a contract award by the Centers for Disease Control and Prevention (CDC) valued at $26...
Emergent BioSolutions and Valneva Initiate Phase 1 Clinical Study to Evaluate Vaccine Candidate Against Zika Virus
GAITHERSBURG, Md. and LYON, France, Feb. 26, 2018 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) and Valneva SE (Euronext Paris:VLA) today announced the initiation of a Phase 1...